STS Administration on Coronavirus Disease (COVID-19) Patients in Critical Care

• Status: Recruiting
• Trial end date: 2023-02-28
• Target enrollment: 0
• Participant gender: All

Summary

The primary purpose is to describe the safety of administration of three doses of STS to critically ill patients with confirmed COVID-19. A secondary purpose is to describe data on the clinical efficacy of administration of up to three doses of STS in critically ill patients with confirmed COVID-19.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hellenic Institute for the Study of Sepsis
• Treatments: Sodium thiosulfate

Criteria

Inclusion Criteria:

1. Age equal to or older than 18 years

2. Both genders

3. For women of childbearing potential, they must use or be willing to use a dual contraceptive method during the study.

4. Written consent statement provided by the patient or his / her legal representative in case patients are unable to consent.

5. Confirmed COVID-19 disease

6. WHO-CPS 7 to 9

7. Hospitalization in Intensive Care Unit

8. Serum H2S levels less than 140 μM

Exclusion Criteria:

1. Age less than 18 years

2. Denial of written consent

3. Decision not to resuscitate